

MAR 20 2009

Special 510(k) Premarket Notification  
*NuVasive® Helix-T ACP System***VII. 510(k) Summary**

In accordance with Title 21 of the Code of Federal Regulations, Part 807, and in particular §807.92, the following summary of information is provided:

**A. Submitted by:**

Han Fan  
Regulatory Affairs Associate  
NuVasive, Incorporated  
7475 Lusk Blvd.  
San Diego, California 92121  
Telephone: (858) 909-3338  
Fax: (858) 909-3438

**B. Device Name**

|                            |  |
|----------------------------|--|
| Trade or Proprietary Name: | <i>NuVasive Helix-T Anterior Cervical Plate System</i> |
| Common or Usual Name:      | Cervical Plate and Screw System                        |
| Classification Name:       | Spinal Intervertebral Body Fixation Orthosis           |
| Device Class:              | Class II   |
| Classification:            | §888.3060  |
| Product Code:              | KWQ  |

**C. Predicate Devices**

The subject *Helix-T ACP System* is substantially equivalent to the *Helix ACP System* currently distributed commercially in the U.S. by NuVasive.

**D. Device Description**

The *NuVasive Helix-T ACP System* consists of a variety of types and sizes of plates and attachment screws. Implant components can be rigidly locked into a variety of different configurations to suit the individual pathology and anatomical conditions of the patient.

**E. Intended Use**

The *NuVasive® HELIX-T ACP System* is intended for anterior screw fixation of the cervical spine. These implants have been designed to provide stabilization as an adjunct to cervical fusion. Indications for the use of this implant system include degenerative disc disease defined as neck pain of discogenic origin with the degeneration of the disc confirmed by history and radiographic studies, spondylolisthesis, trauma, spinal stenosis, deformity, tumor, pseudarthrosis or failed previous fusion.

**WARNING:** The *NuVasive HELIX-T ACP System* is not intended for screw attachment or fixation to the posterior elements (pedicles) of the cervical, thoracic or lumbar spine.

**F. Comparison to Predicate Devices**

The subject device has indications for use identical to those of its predicate, and employs the same principles of operation.

**G. Summary of Non-Clinical Tests**

Mechanical testing was presented.

**H. Summary of Clinical Tests**

(Not Applicable).



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Nuvasive, Inc.  
% Han Fan  
Regulatory Affairs Associate  
7475 Lusk Boulevard  
San Diego, California 92121

MAR 20 2009

Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

Re: K083341

Trade/Device Name: HELIX-Anterior Cervical Plating System  
Regulation Number: 21 CFR 888.3060  
Regulation Name: Spinal intervertebral body fixation orthosis  
Regulatory Class: II  
Product Code: KWQ  
Dated: March 16, 2009  
Received: March 17, 2009

Dear Han Fan:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Center for Devices and Radiological Health's (CDRH's) Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (240) 276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at (240) 276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at toll-free number (800) 638-2041 or (240) 276-3150 or the Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely yours,

A handwritten signature in black ink, appearing to read 'Mark N. Melkerson', is written over a horizontal line.

Mark N. Melkerson  
Director  
Division of General, Restorative  
and Neurological Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure

## Indications for Use

510(k) Number (if known): \_\_\_\_\_

Device Name: HELIX-T Anterior Cervical Plating System

Indications For Use:

The NuVasive HELIX Anterior Cervical Plating System is intended for anterior screw fixation of the cervical spine. These implants have been designed to provide stabilization as an adjunct to cervical fusion. Indications for the use of this implant system include degenerative disc disease defined as neck pain of discogenic origin with the degeneration of the disc confirmed by history and radiographic studies, spondylolisthesis, trauma, spinal stenosis, deformity, tumor, pseudarthrosis or failed previous fusion.

**WARNING:** The NuVasive HELIX-T Anterior Cervical Plating System is not intended for screw attachment or fixation to the posterior elements (pedicles) of the cervical, thoracic or lumbar spine.

Prescription Use ☒  
(Part 21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use \_\_\_\_\_  
(21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

---

Concurrence of CDRH, Office of Device Evaluation (ODE)

  
(Division Sign-Off)

Division of General, Restorative,  
and Neurological Devices

Page 1 of 1

510(k) Number \_\_\_\_\_

14083341